Stoke Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $9,325 | $6,229 | $1,402 | $10,632 |
Gross Profit | 8,186 | 5,182 | 347 | 9,643 |
EBITDA | -64,291 | -45,559 | -56,876 | -38,633 |
EBIT | -65,429 | -46,605 | -57,931 | -39,622 |
Net Income | -61,618 | -50,003 | -57,934 | -38,347 |
Net Change In Cash | 9,325 | 6,229 | 1,402 | 10,632 |
Free Cash Flow | -58,561 | -60,935 | -30,686 | -30,498 |
Cash | 110,004 | 155,659 | 84,220 | 83,394 |
Basic Shares | 66,017 | 63,063 | 58,389 | 58,611 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $184,420 | $36,555 | $8,780 | $12,405 |
Gross Profit | 184,420 | 36,555 | 8,780 | 12,405 |
EBITDA | -5,115 | -86,804 | -102,230 | -102,810 |
EBIT | -6,885 | -88,981 | -104,699 | -104,356 |
Net Income | -6,885 | -88,981 | -104,699 | -93,110 |
Net Change In Cash | 184,420 | 36,555 | 8,780 | 12,405 |
Cost of Revenue | -31,339 | |||
Free Cash Flow | 44,915 | -87,054 | -82,683 | -35,828 |
Cash | 84,220 | 127,983 | 191,442 | 113,556 |
Basic Shares | 59,219 | 54,008 | 43,994 | 38,897 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.93 |
2026-03-31 | -$0.79 |
2025-12-31 | -$0.97 |
2025-09-30 | -$0.65 |